Sage and Bojian SAGE-324 Phase II tremor test reached the primary endpoint

CompilationFan Dongdong

A few days ago, Sage Pharmaceuticals and Biogen announced that the Phase 2 KINETIC trial evaluating SAGE-324 in patients with essential tremor (ET) reached the primary endpoint.

The trial mainly evaluated the therapeutic effect of SAGE-324 in a higher dose range.

The results of the test showed that in the KINETIC trial (n=67), compared with placebo, patients received the GABAA receptor positive modulator SAGE-324 for 29 days after treatment, the basic tremor rating scale (TETRAS) performance subscale item 4 In the upper extremity tremor score, the primary endpoint of statistically significant reduction was reached (p=0.

During the 28-day KINETIC trial treatment period, the study patients did not take other ET treatment drugs.

In addition, in terms of safety, the treatment-related emergency adverse events (TEAE) found by patients in the trial so far are generally consistent with the safety of the previous SAGE-324.

SAGE-324 is a research-type oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator.

At present, Bojian and Sage are satisfied with the latest progress made by SAGE-324, and are planning to advance the next step of SAGE-324 development work.

Reference source:

1.